Tag: genentech

June 12, 2019

FDA Grants Priority Review to Genentech’s Rituxan

Genentech, which falls under the Roche Group (OTCQX:RHHBY) umbrella, has recieved priority review from the US Food and Drug Administration...
November 22, 2018

Genentech’s Venclexta Receives New FDA Approval

As per the announcement, the FDA has given Venclexta accelerated approval for newly diagnosed acute myeloid leukemia patients.
November 22, 2018

Genentech Announces FDA Grants Venclexta Accelerated Approval

Genentech, a member of the Roche Group (SIX:RO,ROG;OTCQX:RHHBY), announced that the U.S. Food and Drug Administration (FDA) has granted accelerated...
September 24, 2018

Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death

Genentech, a member of the Roche Group (SIX:RO,ROG;OTCQX:RHHBY) announced results from the Phase III IMpower132 study of TECENTRIQ (atezolizumab) plus pemetrexed...
June 8, 2018

FDA Approves Genentech’s Rituxan (rituximab) For Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration...
April 30, 2018

8 Glioblastoma Treatment Stocks

With an average survival rate of 16 months, glioblastoma is the most common and deadly type of brain cancer, accounting...
March 20, 2018

AC Immune reports full-year 2017 financial results

AC Immune (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced...